Trade Report: The DexCom Inc. (DXCM) to Release Quarterly Earnings on Tuesday

The DexCom Inc. (DXCM) to Release Quarterly Earnings on Tuesday

DexCom Inc. (NASDAQ:DXCM) is set to issue its Q316 quarterly earnings data on Tuesday, November 1st. Analysts expect the company to announce earnings of ($0.13) per share and revenue of $146.09 million for the quarter.

Shares of DexCom Inc. (NASDAQ:DXCM) opened at 76.70 on Monday. The firm’s market cap is $6.43 billion. DexCom Inc. has a 12-month low of $47.92 and a 12-month high of $96.38. The company has a 50-day moving average of $86.23 and a 200 day moving average of $79.46.

DXCM has been the subject of several research reports. Zacks Investment Research cut DexCom from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 4th. Desjardins raised DexCom from a “hold” rating to a “buy” rating in a research report on Friday, September 16th. Benchmark Co. reduced their price objective on DexCom from $106.00 to $86.00 and set a “buy” rating for the company in a research report on Wednesday, August 3rd. Jefferies Group reaffirmed a “positive” rating and issued a $98.00 target price on shares of DexCom in a research report on Friday, July 22nd. Finally, BTIG Research cut DexCom from a “buy” rating to a “neutral” rating and set a $92.00 target price for the company. in a research report on Wednesday, September 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $95.40.

In related news, insider Terrance H. Gregg sold 10,740 shares of DexCom stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $95.29, for a total value of $1,023,414.60. Following the completion of the sale, the insider now directly owns 451,486 shares in the company, valued at $43,022,100.94. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mark G. Foletta sold 1,800 shares of DexCom stock in a transaction dated Wednesday, September 7th. The stock was sold at an average price of $94.63, for a total value of $170,334.00. The disclosure for this sale can be found here. 2.80% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. raised its stake in shares of DexCom by 1.2% in the second quarter. Point72 Asset Management L.P. now owns 261,000 shares of the medical device company’s stock worth $20,705,000 after buying an additional 3,100 shares during the last quarter. Paulson & CO. Inc. raised its stake in shares of DexCom by 199.0% in the second quarter. Paulson & CO. Inc. now owns 123,500 shares of the medical device company’s stock worth $9,797,000 after buying an additional 82,200 shares during the last quarter. EverPoint Asset Management LLC purchased a new stake in shares of DexCom during the second quarter worth approximately $5,950,000. Jane Street Group LLC raised its stake in shares of DexCom by 1.8% in the second quarter. Jane Street Group LLC now owns 18,384 shares of the medical device company’s stock worth $1,458,000 after buying an additional 325 shares during the last quarter. Finally, Capital World Investors purchased a new stake in shares of DexCom during the second quarter worth approximately $10,392,000. Hedge funds and other institutional investors own 99.35% of the company’s stock.

DexCom Company Profile

Related posts

Leave a Comment